TY - JOUR
T1 - Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease
AU - Sims, Rebecca
AU - van der Lee, Sven J
AU - Naj, Adam C
AU - Bellenguez, Céline
AU - Badarinarayan, Nandini
AU - Jakobsdottir, Johanna
AU - Kunkle, Brian W
AU - Boland, Anne
AU - Raybould, Rachel
AU - Bis, Joshua C
AU - Martin, Eden R
AU - Grenier-Boley, Benjamin
AU - Heilmann-Heimbach, Stefanie
AU - Chouraki, Vincent
AU - Kuzma, Amanda B
AU - Sleegers, Kristel
AU - Vronskaya, Maria
AU - Ruiz, Agustin
AU - Graham, Robert R
AU - Olaso, Robert
AU - Hoffmann, Per
AU - Grove, Megan L
AU - Vardarajan, Badri N
AU - Hiltunen, Mikko
AU - Nöthen, Markus M
AU - White, Charles C
AU - Hamilton-Nelson, Kara L
AU - Epelbaum, Jacques
AU - Maier, Wolfgang
AU - Choi, Seung-Hoan
AU - Beecham, Gary W
AU - Dulary, Cécile
AU - Herms, Stefan
AU - Smith, Albert V
AU - Funk, Cory C
AU - Derbois, Céline
AU - Forstner, Andreas J
AU - Ahmad, Shahzad
AU - Li, Hongdong
AU - Bacq, Delphine
AU - Harold, Denise
AU - Satizabal, Claudia L
AU - Valladares, Otto
AU - Lupton, Michelle K
AU - Proitsi, Petra
AU - Hodges, Angela
AU - Patel, Yogen
AU - Al-Chalabi, Ammar
AU - Shaw, Christopher E
AU - Powell, John
AU - ARUK Consortium
PY - 2017/9/1
Y1 - 2017/9/1
N2 - We identified rare coding variants associated with Alzheimer's disease in a three-stage case-control study of 85,133 subjects. In stage 1, we genotyped 34,174 samples using a whole-exome microarray. In stage 2, we tested associated variants (P < 1 × 10(-4)) in 35,962 independent samples using de novo genotyping and imputed genotypes. In stage 3, we used an additional 14,997 samples to test the most significant stage 2 associations (P < 5 × 10(-8)) using imputed genotypes. We observed three new genome-wide significant nonsynonymous variants associated with Alzheimer's disease: a protective variant in PLCG2 (rs72824905: p.Pro522Arg, P = 5.38 × 10(-10), odds ratio (OR) = 0.68, minor allele frequency (MAF)cases = 0.0059, MAFcontrols = 0.0093), a risk variant in ABI3 (rs616338: p.Ser209Phe, P = 4.56 × 10(-10), OR = 1.43, MAFcases = 0.011, MAFcontrols = 0.008), and a new genome-wide significant variant in TREM2 (rs143332484: p.Arg62His, P = 1.55 × 10(-14), OR = 1.67, MAFcases = 0.0143, MAFcontrols = 0.0089), a known susceptibility gene for Alzheimer's disease. These protein-altering changes are in genes highly expressed in microglia and highlight an immune-related protein-protein interaction network enriched for previously identified risk genes in Alzheimer's disease. These genetic findings provide additional evidence that the microglia-mediated innate immune response contributes directly to the development of Alzheimer's disease.
AB - We identified rare coding variants associated with Alzheimer's disease in a three-stage case-control study of 85,133 subjects. In stage 1, we genotyped 34,174 samples using a whole-exome microarray. In stage 2, we tested associated variants (P < 1 × 10(-4)) in 35,962 independent samples using de novo genotyping and imputed genotypes. In stage 3, we used an additional 14,997 samples to test the most significant stage 2 associations (P < 5 × 10(-8)) using imputed genotypes. We observed three new genome-wide significant nonsynonymous variants associated with Alzheimer's disease: a protective variant in PLCG2 (rs72824905: p.Pro522Arg, P = 5.38 × 10(-10), odds ratio (OR) = 0.68, minor allele frequency (MAF)cases = 0.0059, MAFcontrols = 0.0093), a risk variant in ABI3 (rs616338: p.Ser209Phe, P = 4.56 × 10(-10), OR = 1.43, MAFcases = 0.011, MAFcontrols = 0.008), and a new genome-wide significant variant in TREM2 (rs143332484: p.Arg62His, P = 1.55 × 10(-14), OR = 1.67, MAFcases = 0.0143, MAFcontrols = 0.0089), a known susceptibility gene for Alzheimer's disease. These protein-altering changes are in genes highly expressed in microglia and highlight an immune-related protein-protein interaction network enriched for previously identified risk genes in Alzheimer's disease. These genetic findings provide additional evidence that the microglia-mediated innate immune response contributes directly to the development of Alzheimer's disease.
KW - Journal Article
U2 - 10.1038/ng.3916
DO - 10.1038/ng.3916
M3 - Article
C2 - 28714976
SN - 1061-4036
VL - 49
SP - 1373
EP - 1384
JO - Nature Genetics
JF - Nature Genetics
ER -